The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback